11:18:14 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-01-28 Bokslutskommuniké 2024
2024-10-24 Kvartalsrapport 2024-Q3
2024-07-12 Kvartalsrapport 2024-Q2
2024-04-26 X-dag ordinarie utdelning XVIVO 0.00 SEK
2024-04-25 Årsstämma 2024
2024-04-24 Kvartalsrapport 2024-Q1
2024-01-25 Bokslutskommuniké 2023
2023-10-24 Kvartalsrapport 2023-Q3
2023-07-13 Kvartalsrapport 2023-Q2
2023-04-26 X-dag ordinarie utdelning XVIVO 0.00 SEK
2023-04-25 Årsstämma 2023
2023-04-24 Kvartalsrapport 2023-Q1
2023-01-26 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-07-13 Kvartalsrapport 2022-Q2
2022-04-27 X-dag ordinarie utdelning XVIVO 0.00 SEK
2022-04-26 Årsstämma 2022
2022-04-25 Kvartalsrapport 2022-Q1
2022-01-27 Bokslutskommuniké 2021
2021-10-28 Kvartalsrapport 2021-Q3
2021-07-13 Kvartalsrapport 2021-Q2
2021-04-23 X-dag ordinarie utdelning XVIVO 0.00 SEK
2021-04-22 Årsstämma 2021
2021-04-21 Kvartalsrapport 2021-Q1
2021-01-28 Bokslutskommuniké 2020
2020-10-23 Kvartalsrapport 2020-Q3
2020-10-14 Extra Bolagsstämma 2020
2020-07-10 Kvartalsrapport 2020-Q2
2020-04-09 Kvartalsrapport 2020-Q1
2020-04-01 X-dag ordinarie utdelning XVIVO 0.00 SEK
2020-03-31 Årsstämma 2020
2020-01-30 Bokslutskommuniké 2019
2019-10-24 Kvartalsrapport 2019-Q3
2019-07-12 Kvartalsrapport 2019-Q2
2019-04-26 X-dag ordinarie utdelning XVIVO 0.00 SEK
2019-04-25 Årsstämma 2019
2019-04-24 Kvartalsrapport 2019-Q1
2019-02-08 Bokslutskommuniké 2018
2018-10-26 Kvartalsrapport 2018-Q3
2018-07-13 Kvartalsrapport 2018-Q2
2018-04-30 X-dag ordinarie utdelning XVIVO 0.00 SEK
2018-04-27 Årsstämma 2018
2018-04-26 Kvartalsrapport 2018-Q1
2018-02-09 Bokslutskommuniké 2017
2017-10-27 Kvartalsrapport 2017-Q3
2017-07-14 Kvartalsrapport 2017-Q2
2017-04-27 X-dag ordinarie utdelning XVIVO 0.00 SEK
2017-04-26 Årsstämma 2017
2017-04-25 Kvartalsrapport 2017-Q1
2017-04-10 Extra Bolagsstämma 2017
2017-02-08 Bokslutskommuniké 2016
2016-10-27 Kvartalsrapport 2016-Q3
2016-07-15 Kvartalsrapport 2016-Q2
2016-05-04 X-dag ordinarie utdelning XVIVO 0.00 SEK
2016-05-03 Årsstämma 2016
2016-04-26 Kvartalsrapport 2016-Q1
2016-02-04 Bokslutskommuniké 2015
2015-10-23 Kvartalsrapport 2015-Q3
2015-08-13 Kvartalsrapport 2015-Q2
2015-04-24 X-dag ordinarie utdelning XVIVO 0.00 SEK
2015-04-23 Årsstämma 2015
2015-04-22 Kvartalsrapport 2015-Q1
2015-02-05 Bokslutskommuniké 2014
2014-10-24 Kvartalsrapport 2014-Q3
2014-10-24 Analytiker möte 2014
2014-08-13 Kvartalsrapport 2014-Q2
2014-04-30 X-dag ordinarie utdelning XVIVO 0.00 SEK
2014-04-29 Årsstämma 2014
2014-04-23 Kvartalsrapport 2014-Q1
2014-02-07 Bokslutskommuniké 2013
2013-11-07 Analytiker möte 2013
2013-11-07 Kvartalsrapport 2013-Q3
2013-07-11 Kvartalsrapport 2013-Q2
2013-05-08 X-dag ordinarie utdelning XVIVO 0.00 SEK
2013-05-07 Årsstämma 2013
2013-04-19 Kvartalsrapport 2013-Q1
2013-02-19 Bokslutskommuniké 2012
2012-11-01 Kvartalsrapport 2012-Q3

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Xvivo Perfusion är verksamt inom medicinteknik. Bolaget tillhandahåller lösningar för transplantation av lungor. Exempel på produkter som bolaget levererar innefattar kanyler, organförvaring samt kyllösningar. Produkterna vidaresäljs till kliniker och forskningsinstitut runtom den globala marknaden, med störst närvaro inom Norden och Europa. Bolaget kom till via en avknoppning från Vitrolife under 2012 och har sitt huvudkontor i Göteborg.
2024-01-25 07:30:00

Fourth quarter 2023 (October 1 - December 31)
• Net sales amounted to SEK 155.7 million (131.5), corresponding to an increase of 18 percent in SEK and 16 percent in local currencies.
• Organic growth accounted for 12 percent and acquired growth for 4 percent.
• All business areas delivered underlying organic growth adjusted for currency effects: Thoracic disposables 14 percent, Abdominal disposables 22 percent and Services 18 percent.
• The gross margin for disposables increased to 81 percent (79). The total gross margin was 75 percent (72).
• Operating income (EBIT) amounted to SEK -16.1 million (2.3) and includes a write-down related to PrimECC totaling SEK -16.4 million. Adjusted EBIT amounted to SEK 0.8 million (8.5)
• Operating income before depreciation and amortization (EBITDA) amounted to SEK 20.7 million (13.6) corresponding to an EBITDA margin of 13 percent (10). Adjusted operating income before depreciation and amortization (EBITDA) amounted to SEK 21.2 million (19.8), corresponding to an adjusted EBITDA margin of 14 percent (15).
• Net profit amounted to SEK 68.5 million (0.7) and was impacted by financial income of SEK 73.7 million (8.9) attributable to fair value valuation of financial liabilities.
• Earnings per share amounted to SEK 2.17 (0.02).
• Cash flow from operating activities amounted to SEK 18.1 million (21.8), primarily due to positive operating income before depreciation and amortization. Total cash flow amounted to SEK -38.2 million (-58.1) impacted by investments in R&D projects of SEK -33.3 million (-26.2).

Significant events during the quarter
• First transplant completed in the US heart preservation trial
• Results from Australian/New Zealand study using XVIVO’s heart technology published
• Milestone reached in Italy with 1,200 lifesaving perfusions performed with Liver Assist
• Write-down related to PrimECC of SEK 17 million which does not affect cash flow or EBITDA
• Financial income of SEK 69.0 million recognized, attributable to write-down of financial liabilities after fair value valuation, not affecting cash flow, operating income (EBIT) or EBITDA
• XVIVO Perfusion Lund AB was merged with the parent company XVIVO Perfusion AB

The period 2023 (January 1 - December 31)
• Net sales amounted to SEK 597.5 million (415.3), corresponding to an increase of 44 percent in SEK and 36 percent in local currencies.
• Organic growth accounted for 30 percent and acquired growth for 6 percent.
• All business areas delivered underlying organic growth adjusted for currency effects: Thoracic disposables 28 percent, Abdominal disposables 53 percent and Services 57 percent.
• Gross margin for disposables increased to 81 percent (79). The total gross margin was 74 percent (72).
• Operating income (EBIT) amounted to SEK 4.2 million (6.4) and includes a write-down related to PrimECC totaling SEK -16.4 million and integration costs SEK-22.1 million. Adjusted EBIT amounted to SEK 42.7 million (14.3).
• Operating income before depreciation and amortization (EBITDA) amounted to SEK 80.5 million (48.6), corresponding to an EBITDA margin of 13 percent (12). Adjusted EBITDA amounted to SEK 102.6 million (56.5), corresponding to an adjusted EBITDA margin of 17 percent (14).
• Net profit amounted to SEK 91.8 million (18.4) and was impacted by financial income of SEK 72.0 million (-21.5) attributable to fair value valuation of financial liabilities.
• Earnings per share amounted to SEK 3.07 (0.62).
• Cash flow from operating activities increased to SEK 46.3 million (27.9). Total cash flow amounted to SEK 303.2 million (-176.6), primarily comprising net proceeds from a new issue totaling SEK 440 million, payment of contingent consideration from the acquisition of Avionord (XVIVO S.r.l.) of SEK -10.9 million, the final part payment of the initial purchase consideration regarding the acquisition of STAR Teams of SEK -6.8 million and investments in R&D projects of SEK -100.1 million (-111.6).

Significant events in the reporting period
• Successful integration of Avionord M&P
• A pre-clinical study published in The Journal of Heart and Lung Transplantation demonstrated advantages associated with XVIVO’s heart preservation technology, even in DCD donations
• Significant interest in XVIVO’s heart technology in Australia and New Zealand. Approximately 30 percent of these countries’ heart transplants were performed using XVIVO’s technology in the period through special permits pending regulatory approval
• A large multicenter study published in The Journal of Hepathology demonstrated improved evidence for the advantages of oxygenated cold perfusion of liver in donation after brain death (DBD)
• Patient inclusion completed in European clinical trial using heart preservation technology
• US FDA grants XVIVO approval to start its IDE clinical study in heart preservation and to include DCD hearts in IDE Clinical Trial in the US
• XVIVO’s heart preservation technology has enabled a second xenotransplant (heart from pig to human)
• The US service offering strengthened by commercial integration of STAR Teams and by a strategic collaboration with MTJ Aviation.
• A directed share issue raised SEK 440 million before transaction costs and was completed with no discount
• The number of shares and votes in XVIVO Perfusion AB (publ) increased by 1,667,551, to a total of 31,499,470 shares and votes.
• Further patient inclusion in the PrimECC study halted.

Events after the end of the period
• UMCG in Groningen, the Netherlands, has demonstrated that prolonged liver perfusion can streamline planning and logistics and enable more liver transplants to be performed during daytime
• The Board of Directors proposes that no dividend be paid for the 2023 financial year and that retained earnings be carried forward